ARTNet focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence. Its central goal is to balance basic, pre-clinical, and translational research using an iterative team science structure that will enable hypothesis testing on the biological basis of resistance in clinically relevant model systems. ARTNet also aims to provide evidence along the shared tumor-tumor microenvironment (TME) continuum to inform new strategies that can be better translated into future clinical trials.
The ARTNet is supported by NIH Cancer MoonshotSM. The Cancer MoonshotSM aims to accelerate cancer research to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.